A global measure to assess switching antipsychotic medications in the treatment of schizophrenia

Human Psychopharmacology

Volumn 27, Issue 5, 2012, Pages 455-463

  Targum, Steven D ^a   Pestreich, Linda ^b   Reksoprodjo, Petra ^c   Pereira, Heidi ^b   Guindon, Carrie ^b   Hochfeld, Marla ^b  

^a Clintara LLC   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

^c Psychiatry   (Czech Republic)

Author keywords

CGI severity; schizophrenia; switching antipsychotics

Indexed keywords

ARIPIPRAZOLE; ILOPERIDONE; NEUROLEPTIC AGENT; OLANZAPINE; RISPERIDONE;

ADULT; AKATHISIA; ANXIETY; ARTICLE; CLINICAL ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HUMAN; INTERRATER RELIABILITY; MALE; MODIFIED CLINICAL GLOBAL IMPRESSION SCALE SWITCH INSTRUMENT; PRIORITY JOURNAL; PSYCHOSIS; SCHIZOPHRENIA; SEDATION; SIDE EFFECT; SOMNOLENCE; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; FEMALE; HUMANS; MALE; MIDDLE AGED; OBSERVER VARIATION; PSYCHIATRIC STATUS RATING SCALES; REPRODUCIBILITY OF RESULTS; SCHIZOPHRENIA; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84866733002     PISSN: 08856222     EISSN: 10991077     Source Type: Journal    
DOI: 10.1002/hup.2247     Document Type: Article

References (24)

1. American Psychiatric Association. 2009. Atypical antipsychotics position statement. Available at http://www.psych.org/Departments/EDU/Library/ APAOfficialDocumentsandRelated/PositionStatements/2009.
2. Busner J, Targum SD,. 2007. The clinical global impressions scale: applying a research tool in clinical practice. Psychiatry 4: 28-37.
3. Chen M, Kianifard F,. 2000. A nonparametric procedure associated with a clinically meaningful efficacy measure. Biostatistics 1: 293-298.
4. Diggle PJ, Heagerty P, Liang KY, Zeger SL,. 2002. Analysis of Longitudinal Data, 2ndedn. Oxford University Press: Oxford.
5. Essock SM, Covell NH, Davis SM, Stroup S, Rosenheck RA, Lieberman JA,. 2006. Effectiveness of switching antipsychotic medications. Am J Psychiatry 163: 2090-2095.
6. Ganguli R,. 2002. Rationale and strategies for switching antipsychotics. Am J Health Syst Pharm 59 (suppl 8): S22-S26.
7. Goodman WK, Price LH, Rasmussen SA, et al,. 1989. The Yale-Brown Obsessive Compulsive Scale. Arch Gen Psychiatry 46: 1012-1016.
8. Guy W,. 1976. ECDEU assessment manual for psychopharmacology. DHEW Publication ADM-76-338; 534-537.
9. Kadouri A, Corruble E, Falissard B,. 2007. The improved Clinical Global Impression Scale (iCGI): development and validation in depression. BMC Psychiatry 7: 1-7.
10. Leucht S, Davis JM, Engel RR, Kissling W, Kane JM,. 2009. Definitions of response and remission in schizophrenia: recommendations for their use and their presentation. Acta Psychiatr Scand Suppl 438: 7-14.
11. Levine SZ, Rabinowitz J, Engel R, Etschel E, Leucht S,. 2008. Extrapolation between measures of symptom severity and change: an examination of the PANSS and CGI. Schizophr Res 98: 318-322.
12. Levine SZ, Rabinowitz J, Ascher-Svanum H, Faries DE, Lawson AH,. 2011. Extent of attaining and maintaining symptom remission by antipsychotic medication in the treatment of chronic schizophrenia: evidence from the CATIE study. Schizophr Res 133: 42-46.
13. Lieberman JA, Stroup TS, McEvoy JP, et al,. 2005. Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353: 1209-1223.
14. Liu-Seifert H, Adams DH, Kinon BJ,. 2005. Discontinuation of treatment of schizophrenic patients is driven by poor symptom response: a pooled post-hoc analysis of four atypical antipsychotic drugs. BMC Med 23 (3): 21.
15. Potkin SG, Litman RE, Torres R, et al,. 2008. Efficacy of iloperidone in the treatment of schizophrenia: initial phase 3 studies. J Clin Psychopharmacol 28 (2Suppl 1): S4-S11.
16. Rabinowitz J, Levine S, Martinez G,. 2010. Concordance between measures of functioning, symptoms, and change examining the GAF, CGI-S, CGI-C, and PANSS. J Clinical Psychopharmacol 30: 478-480.
17. Remington G, Chue P, Stip E, Kopala L, Girard T, Christensen B,. 2005. The crossover approach to switching antipsychotics: what is the evidence? Schizophr Res 76: 267-272.
18. Schneider LS, Olin JT, Doody RS, et al,. 1997. Validity and reliability of the Alzheimer's Disease Cooperative Study - Clinical Global Impression of Change. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord 11 (Suppl 2): S22-S23.
19. Spearing M, Post RM, Leverich GS, Brandt D, Nolen W,. 1997. Modification of the Clinical Global Impression (CGI) Scale for use in bipolar illness (BP): the CGI-BP. Psychiatry Res 73: 159-171.
20. Stroup TS, Lieberman JA, McEvoy JP, et al,. 2006. Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. Am J Psychiatry 163: 611-622.
21. Targum SD, Busner J, Young AH,. 2008. Targeted scoring criteria reduces variance in global impressions. Hum Psychopharmacol Clin Exp 23: 628-633.
22. Targum SD, Hassman H, Pinho M, Fava M,. 2012. Development of a clinical global impression scale for fatigue. J Psychiatr Res 46: 370-374.
23. Valenstein M, Blow FC, Copeland LA, et al,. 2004. Poor antipsychotic adherence among patients with schizophrenia: medication and patient factors. Schizophr Bull 30 (2): 255-264.
24. Voruganti L, Cortese L, Owyeumi L, et al,. 2002. Switching from conventional to novel antipsychotic drugs: results of a prospective naturalistic study. Schizophr Res 57: 201-208.